Home Stock

Stock Research: Aquestive Therapeutics

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Aquestive Therapeutics

NMQ:AQST US03843E1047
76
  • Value
    86
  • Growth
    46
  • Safety
    Safety
    13
  • Combined
    47
  • Sentiment
    85
  • 360° View
    360° View
    76
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Aquestive Therapeutics, Inc. is a pharmaceutical company developing orally administered and topical gel products. It operates in the pharmaceutical industry with products like Anaphylm, AQST-108, Libervant, Suboxone, and Emylif, and commercializes its products in the United States and globally through licensees. In the last fiscal year, the company had a market cap of $403 million, profits of $40 million, revenue of $58 million, and 142 employees.

more

ANALYSIS: With an Obermatt 360° View of 76 (better than 76% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Aquestive Therapeutics are very positive. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Aquestive Therapeutics. The consolidated Value Rank has an attractive rank of 86, which means that the share price of Aquestive Therapeutics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 86% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 85, which means that professional investors are more optimistic about the stock than for 85% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 46, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 13, meaning the company has a riskier financing structure than 87 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Market Pulse
Country USA
Industry Pharmaceuticals
Size Small
Website aquestive.com
Index
NASDAQ
Aquestive Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
86 49 51 73
Growth
46 31 99 13
Safety
Safety
13 69 40 29
Sentiment
85 50 73 70
360° View
360° View
76 44 93 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
67 85 88 61
Opinions Change
50 50 50 94
Pro Holdings
n/a 49 83 55
Market Pulse
98 21 11 8
Sentiment
85 50 73 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
86 49 51 73
Growth
46 31 99 13
Safety Safety
13 69 40 29
Combined
47 51 83 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
41 15 33 62
Price vs. Earnings (P/E)
77 42 42 42
Price vs. Book (P/B)
84 93 89 92
Dividend Yield
1 1 1 1
Value
86 49 51 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
51 1 55 49
Profit Growth
44 4 91 33
Capital Growth
49 91 81 13
Stock Returns
60 75 95 41
Growth
46 31 99 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
1 74 46 38
Refinancing
32 65 49 43
Liquidity
51 29 31 34
Safety Safety
13 69 40 29

Similar Stocks

Discover high‑ranked alternatives to Aquestive Therapeutics and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Peabody Energy

NYQ:BTU
Country: USA
Industry: Coal & Consumable Fuels
Size: Large
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews